Sera Prognostics, Inc. SERA
Medical Specialities · IPO 2021 · data as of November 13, 2026
Sera Prognostics, Inc. (SERA) is a healthcare company listed in the US with a market value of about $80M. In the twelve months to September 30, 2026 it had revenue of $96000 and net income of -$33M, a net margin of -34866.7%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 27% a year, a 5-year average ROIC of -45%.
About Sera Prognostics
Sera Prognostics is listed in the US and classified in medical specialities, IPO year 2021. Revenue went from $25000 in 2020 to $81000 in 2025, growth of about 26.5% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 54% over three years (dilution for shareholders). It spends 16260% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $96000 | $81000 | $77000 | $306000 | $268000 | $82000 | $25000 |
| Net income | -$33M | -$32M | -$33M | -$36M | -$44M | -$35M | -$20M |
| Free cash flow | -$29M | -$26M | -$14M | -$27M | -$35M | -$33M | -$17M |
| EPS (diluted) | $-0.67 | $-0.67 | $-0.99 | $-1.16 | $-1.43 | $-2.33 | $-12.76 |
| Net margin | -34866.7% | -39417.3% | -42724.7% | -11843.8% | -16487.3% | -42693.9% | -79392.0% |
| ROIC | — | -46.9% | -75.6% | -44.1% | -35.8% | -20.2% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Sera Prognostics pay a dividend?
Not currently.
Is Sera Prognostics a good stock to buy?
We do not give buy or sell advice. Sera Prognostics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.